Zenas Biopharma Inc
ZBIO
View Detailed Chart
21.800USD
+0.790+3.76%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
920.25MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.76%
5 Days
+18.67%
1 Month
+43.42%
6 Months
+38.85%
Year to Date
-39.96%
1 Year
+177.71%
View Detailed Chart
TradingKey Stock Score of Zenas Biopharma Inc
Currency: USD Updated: 2026-02-06Key Insights
Zenas Biopharma Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 42 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 40.75.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zenas Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Zenas Biopharma Inc Highlights
StrengthsRisks
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.00M.
Fairly Valued
The company’s latest PE is -1.72, at a medium 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 389.00 shares of this stock.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
40.750
Target Price
+93.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zenas Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zenas Biopharma Inc Info
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
Ticker SymbolZBIO
CompanyZenas Biopharma Inc
CEOMoulder (Leon O)
Websitehttps://zenasbio.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68866.390
-1103.740 (-1.58%)
282.580
+22.390 (+8.61%)
2048.750
-2.980 (-0.14%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
